David J. Sullivan focuses on Plasmodium falciparum, Immunology, Biochemistry, Hemozoin and Malaria. His Plasmodium falciparum research integrates issues from Genetics, Vector and Pharmacology. The Immunology study combines topics in areas such as Receptor, Endothelium and Blood–brain barrier.
In the field of Biochemistry, his study on Heme, Vacuole and Amino acid overlaps with subjects such as Quinoline. His study in Heme is interdisciplinary in nature, drawing from both Hemoglobin, Protease and Proteolysis. His Malaria study combines topics in areas such as Virology, Small Molecule Libraries, Drug discovery, Superinfection and Drug.
His primary areas of study are Plasmodium falciparum, Malaria, Immunology, Pharmacology and Virology. The various areas that David J. Sullivan examines in his Plasmodium falciparum study include Parasitology, Biochemistry, Molecular biology, Chloroquine and Drug resistance. His work on Hemozoin, Heme, Vacuole and In vitro as part of general Biochemistry study is frequently linked to Quinoline, bridging the gap between disciplines.
His work carried out in the field of Malaria brings together such families of science as Internal medicine and Drug discovery. His work in Pharmacology addresses subjects such as Artemisinin, which are connected to disciplines such as Mefloquine. His research investigates the link between Virology and topics such as Antibody that cross with problems in Convalescent plasma.
The scientist’s investigation covers issues in Immunology, Antibody, Titer, Convalescent plasma and Neutralizing antibody. Neutralization and Malaria are the subjects of his Immunology studies. His Malaria research incorporates elements of Ingestion and Lactic acid.
The concepts of his Antibody study are interwoven with issues in Interleukin 16, Interleukin 8, Cytokine, Interleukin 21 and Chemokine. His Titer research focuses on Serology and how it relates to Antiviral antibody. David J. Sullivan combines subjects such as Cytotoxic T cell, CD8 and T cell with his study of Neutralizing antibody.
His scientific interests lie mostly in Immunology, Titer, Antibody, Convalescent plasma and Neutralizing antibody. His studies deal with areas such as Transmission and Subclinical infection as well as Immunology. As a part of the same scientific family, David J. Sullivan mostly works in the field of Titer, focusing on Serology and, on occasion, Coronavirus disease 2019, Virology and Immunodiagnostics.
His work investigates the relationship between Antibody and topics such as Severe acute respiratory syndrome coronavirus 2 that intersect with problems in Immunoglobulin G, Avidity, Antibody titer and Poisson regression. His work deals with themes such as Antiviral antibody, MHC class I, CD8 and T cell, which intersect with Neutralizing antibody. His work on Severe Malaria, Plasmodium falciparum and Rapid diagnostic test as part of general Malaria study is frequently linked to Mechanism, therefore connecting diverse disciplines of science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hemoglobin metabolism in the malaria parasite Plasmodium falciparum.
Susan E. Francis;David J. Sullivan;Daniel E. Goldberg.
Annual Review of Microbiology (1997)
New uses for old drugs
Curtis R. Chong;David J. Sullivan.
Nature (2007)
Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Evan M. Bloch;Shmuel Shoham;Arturo Casadevall;Bruce S. Sachais.
Journal of Clinical Investigation (2020)
On the molecular mechanism of chloroquine's antimalarial action.
David J. Sullivan;Ilya Y. Gluzman;David G. Russell;Daniel E. Goldberg.
Proceedings of the National Academy of Sciences of the United States of America (1996)
Chemical genetics of Plasmodium falciparum.
W. Armand Guiguemde;Anang A. Shelat;David Bouck;Sandra Duffy.
Nature (2010)
Plasmodium Hemozoin Formation Mediated by Histidine-Rich Proteins
David J. Sullivan;Ilya Y. Gluzman;Daniel E. Goldberg.
Science (1996)
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.
Wesley C. Van Voorhis;John H. Adams;Roberto Adelfio;Roberto Adelfio;Vida Ahyong.
PLOS Pathogens (2016)
A clinical drug library screen identifies astemizole as an antimalarial agent
Curtis R Chong;Xiaochun Chen;Lirong Shi;Jun O Liu.
Nature Chemical Biology (2006)
Theories on malarial pigment formation and quinoline action.
David J Sullivan.
International Journal for Parasitology (2002)
A common mechanism for blockade of heme polymerization by antimalarial quinolines
David J. Sullivan;Hugues Matile;Robert G. Ridley;Daniel E. Goldberg.
Journal of Biological Chemistry (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Johns Hopkins University
National Institutes of Health
Johns Hopkins University
Johns Hopkins University School of Medicine
Johns Hopkins University
Johns Hopkins University School of Medicine
Johns Hopkins University
George Washington University
Washington University in St. Louis
International Centre for Diarrhoeal Disease Research
Arizona State University
Stanford University
Carnegie Mellon University
DuPont (United States)
MIT
Institute of Photonic Sciences
National Institutes of Health
Soochow University
University of Birmingham
Stanford University
Forschungszentrum Jülich
University of Cambridge
University of Palermo
University of Alberta
McMaster University
University of Minnesota